Rorer stock activity
Stock jumped 3 to 45-3/4 on Thursday, Dec. 1 but slipped 1-1/8 to 44-5/8 on Dec. 2 as Rorer continues on acquisition ride. Recent movement could be tied to renewed speculation about interest by Roche and Sanofi in a U.S. acquisition. The market remembers the bids by the two companies at the end of 1987 and beginning of 1988. Rumors may also have been fueled by the reported visit of senior Roche management from Switzerland to Roche Nutley at the end of November....
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
The French biotech's chances of competing with Aimmune's Palforzia in the peanut allergy market have been boosted after US regulators decided that a fresh Phase III trial for the Viaskin Peanut patch would not be required for resubmission.
COVID-19 has not held back GSK's preparations to create the world's largest standalone consumer health business, with CEO Emma Walmsley confirming separation is on track for summer next year.